• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CLNN

CLNN

Clene Inc.

NASDAQHealthcareBiotechnologyUS

USD5.80

+0.04 (+0.68%)

Rating:C

Company Profile

CEO

Robert Etherington

IPO Date

2018-10-18

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.79

Prev. Close

$5.76

Day Low

$5.65

Day High

$5.90

52W Low

$3.25

52W High

$13.50

Market Cap

$0.06B

Volume

0.01M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

36.5%

Avg Negative

1.5%

Avg Neutral

62.2%

News Feed

Clene Reports Second Quarter 2021 Operating and Financial Highlights

GlobeNewsWire·8/10/2021·↑ positive

Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson's Disease and Multiple Sclerosis

GlobeNewsWire·8/5/2021·↑ positive

Clene: Nanomedicines For Neurodegenerative Diseases

Seeking Alpha
·8/3/2021
·↑ positive

Clene to Present at Canaccord Genuity's Annual Growth Conference

GlobeNewsWire·8/3/2021·↑ positive

Clene Added to Membership of Russell 2000® Index

GlobeNewsWire·6/28/2021·↑ positive

Clene Nanomedicine Receives Catalyst Award for Healthy Longevity from U.S. National Academy of Medicine to Accelerate the Development of CNM-Au8 for Neurodegenerative Diseases Associated with Aging

GlobeNewsWire·5/17/2021·↑ positive

Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology

GlobeNewsWire·4/30/2021·↑ positive

Clene Reports Full Year 2020 Operating and Financial Highlights

GlobeNewsWire·3/29/2021·↑ positive

Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLC

GlobeNewsWire·3/10/2021·↑ positive

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

GlobeNewsWire·3/9/2021·↑ positive